Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “CLIMACTERIC”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 379 records · Page 21Linked to original sources
PubMed1981

Ethamsylate in the treatment of climacteric flushing.

Ethamsylate, a non-hormonal agent acting at the capillary level, was compared with a placebo in a double-blind trial of 12 wk duration in 20 post-menopausal patients with hot flushes. Both ethamsylate and placebo patients showed fluctuations in the frequency of flushes during the trial, but there was a significant downward trend in the ethamsylate group. Capillary strength was measured but was not found to be low or to alter during the trial except in 1 patient in the placebo group. No side-effects attributable to trial medication were reported. Other symptoms recorded during the trial were probably climacteric and occurred more frequently during placebo treatment than during treatment with ethamsylate.

Adult↗
PubMed1981

Climacteric hot flash.

No data are available on either quantitative or qualitative aspects of the climacteric hot flash, yet the phenomenon is widely treated despite unknown aetiology. A basic assumption of this study was that a more complete understanding and description of women with hot flashes would identify alternatives to oestrogens used by women for relief of the hot-flash symptom. An exploratory study was undertaken to answer the question: Who is the woman who has hot flashes and what are the characteristics of the hot flashes? The methodology employed was daily self-report by subjects of hot-flash frequency, duration, trigger, origin, spread, intensity and method of coping with it. Analysis of 20 randomly-selected 2 wk self-report record cards revealed no hot-flash pattern among women. A total of 1041 hot flashes were reported. Mean duration of the hot flash was 3.31 min (range 5 sec to 60 min). Neither hot flash origin nor spread was restricted to the upper body in all subjects. Subjects ranked their hot flash as either mild, moderate or severe. Coping strategies used by subjects (external and internal cooling methods) appeared to be related to both duration and severity of the hot flash.

Adult↗
PubMed1981

Climacteric symptoms according to body weight in women of different socio-economic groups.

The people influence of body weight on the climacteric symptoms of 618 selected women in spontaneous post-menopause has been studied bases on data collected at a Geriatric Centre and subsequently incorporated into a postal questionnaire. These cases were divided into 3 groups according to the "obesity degree": (I) less than 5 kg (53.1% of the cases);(II) between 5 and 15 kg (31.7%); and (III) greater than 15 kg (15.2%). The data were also analysed according to the socio-economic groups to which the women belonged. Overweight women, compared with thin women, seemed to suffer less "somatic" symptoms such as hot flushes and perspiration, independently of their socio-economic level. This might well be a consequence of the higher endogenous oestrogen activity. On the contrary, "psychic" symptoms (anxiety, depression, irritability, crying spells) seemed to be more frequent and severe (a) in the "obesity degree" sub-group III, compared with sub-groups I and II, in the women belonging to the higher socio-economic group, and (b) in the sub-groups I and III, compared with sub-group II, in the women belonging to the lower socio-economic group. Such a difference between the socio-economic groups is possibility due to cultural factors. The effects of endogenous oestrogens in the overweight women seem to be easily overruled by the influence of psychological factors.

Aged↗
PubMed1982

Changes in skin blood flow and body temperatures during climacteric hot flushes.

Blood velocity changes in the radial, temporal and lateral thoracic arteries have been measured quantitatively during climacteric hot flushes by means of an ultrasonic velocity meter. In the radial artery the median increase in velocity was 6 times greater than the basal velocity (range 4-10); in both the temporal and the lateral thoracic arteries the median increase was 1.5 (1.5-3). Simultaneous temperature measurements showed a fairly high increase in finger temperatures. An initial increase in temperature on the forehead was followed by a decrease. The core temperature measured on the tympanic membrane decreased. The pattern of blood velocity which increases during hot flushes, is identical to the pattern seen when someone is transferred to an uncomfortably high temperature. This similarity points to the hot flush as a time in which a heat loss occurs. As temperature measurements show no accumulation of heat prior to the flushes, it is reasonable to assume that hot flushes are the result of a central disorder of temperature regulation.

Adult↗
PubMed1982

A randomised, double-blind, cross-over study into the effect of sequential mestranol and norethisterone on climacteric symptoms and biochemical parameters.

A randomised, double-blind, cross-over study into the effect of graded sequential mestranol and norethisterone on climacteric symptoms was performed. The study group consisted of 23 post-menopausal women who had previously undergone hysterectomy. Active therapy resulted in a significant reduction in hot flushes and night sweats. There was a slight improvement in insomnia, lack of energy and confidence but the other symptoms were not significantly altered. A small placebo effect was noted but this was only significant 1 mth after active treatment had been discontinued in the group of women receiving placebo second. Active treatment also resulted in a significant reduction in serum sodium, calcium, albumin, alkaline phosphatase and cholesterol, and increase in serum triglycerides, but no alteration in the other biochemical parameters, weight or blood pressure.

Adult↗
PubMed1983

Efficacy and safety of Org OD 14 in the treatment of climacteric complaints.

To study the effect of Org OD 14 [17 alpha, 17 alpha)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one) on the endometrium, 9 healthy post-menopausal women were given a daily dose of 2.5 mg of Org OD 14 for 100 consecutive days. In addition, during days 91-100 a daily oral dose of 1 mg of lynestrenol was taken by each volunteer. Endometrial biopsies were obtained before the start of treatment and on day 91. At pre-treatment, the endometrium was atrophic in 7 out of 9 volunteers and weakly stimulated in 2 volunteers. On day 91, the endometrium was found atrophic in 8 out of 9 volunteers and weakly stimulated in 1. Breakthrough bleeding occurred in 1 volunteer. After cessation of the combined treatment with Org OD 14 and lynestrenol, withdrawal bleeding occurred only in 1 volunteer. To assess the efficacy of Org OD 14 in the treatment of climacteric complaints a double-blind cross-over study was performed in 29 post-menopausal women. Patients were randomly allocated to Org OD 14 or to placebo as first treatment. Each period of treatment lasted 4 mth; no wash-out period was introduced. Patients took 1 Org OD 14 tablet (2.5 mg) or 1 placebo tablet per day. The patients scored hot flushes and sweating. At the end of the second treatment period, each patient was asked which of the 2 treatments she preferred. Data sufficient to allow for a conclusion were obtained from 20 patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Atrophy↗
PubMed1983

Bereavement and social support at the climacteric.

The relationship between life events and symptoms was examined in a general population sample of Scottish climacteric women within the framework of the concepts and methods developed in the field of life event research. It was found that at least some of the increase in symptoms at that time of life was due to the occurrence of stressful life events. This relationship was a complex one as different types of life events were associated with symptoms in a differential way. In particular, the occurrence of a bereavement involving a close family member and the consequent loss of social support, were found to be significant factors in provoking physical symptoms, but only in the presence of other life stress. These results are discussed in the context of the findings of other life event researchers.

Adult↗
PubMed1984

A new combination of conjugated equine oestrogens and medroxyprogesterone for treatment of climacteric complaints.

Thirty-four post-menopausal women with climacteric complaints were given conjugated equine oestrogens (1.25 mg/day) for 21 days followed by 2 days without hormones and then 5 mg medroxyprogesteroneacetate daily for 5 days. The present trial was designed to study effects on vasomotor symptoms, bleeding patterns and endometrial histopathology. Vasomotor disturbances were completely relieved. No recurrence of symptoms was recorded in the oestrogen-free week. Withdrawal bleedings were regular and slight, which was a positive experience for those women who had previously been treated with other oestrogen-progestogen regimens. In most patients inactive or weak secretory endometrial epithelium was found during treatment. Two women developed differing degrees of hyperplasia after 2.5 and 3 yr, respectively. This fact emphasizes the necessity of adding progestogens for at least 10 days each month even if the oestrogens and progestogens are administered separately. It may also be wise to perform an endometrial biopsy when sex hormones are administered on a long-term basis.

Biopsy↗
PubMed1986

Climacteric complaints as influenced by progestogens.

A general assessment of the usefulness of progestogens in the treatment of climacteric complaints is made, based on evidence from the literature. The effects of progestogens in regard to vasomotor and mental symptoms are considered separately.

Climacteric↗
PubMed1986

A review of study findings of the risks and benefits of oestrogen therapy in the female climacteric.

A literature review was conducted to assess the evidence regarding the risks and benefits of oestrogen therapy in climacteric women. Consideration was given to the route of administration, effects on lipid levels, the skin and urinary symptoms, endometrial cancer, mortality and replacement therapy. It was concluded from the data examined that properly administered oestrogen treatment does not increase the risk of endometrial cancer and that the relative risk of death in oestrogen users aged over 40 is markedly lower than than in non-users.

Adult↗
PubMed1987

Evaluation of a psychological treatment programme for climacteric women.

A psychological assessment and treatment programme designed for a group of climacteric women with severe and varied psychological complaints and symptoms is described and evaluated. All the women were currently experiencing stressful psychosocial difficulties within their life situation. The treatment programme comprised an educational, a counseling and a behavioural component. By the end of the sixth session of therapy, most women showed a significant improvement in their main complaint, accompanied by improvements in general symptoms and personal adjustment. Two-thirds considered that they had benefited substantially from treatment. The outcome of the treatment was considered to be encouraging in what might otherwise be considered a potentially unresponsive group of women.

Adult↗
PubMed1987

Pilot study to evaluate a new regimen to treat climacteric complaints with cyclic combined oestradiol valerate/medroxyprogesterone acetate.

Nineteen post-menopausal women suffering from climacteric complaints were treated with a cyclic regimen comprising 25 days on 2 mg oestradiol valerate and 5 mg medroxyprogesterone acetate daily, followed by a 5-day treatment-free interval. The mean duration of treatment was 20.2 mth. Control of bleeding was good; 9 women had slight monthly bleeding, 8 no bleeding at all, and 2 had only irregular spotting during the follow-up period. An endometrial biopsy was taken in 9 women in whom the mean duration of treatment was 30 mth. All endometrial biopsies showed an atrophic endometrium. A larger, randomized comparative study is now planned.

Adult↗
PubMed1989

The questionable physiologic and epidemiologic basis for a male climacteric syndrome: preliminary results from the Massachusetts Male Aging Study.

This paper examines the physiologic and epidemiologic evidence for a widely discussed syndrome termed either 'mid-life crisis', 'male menopause', 'male climacteric', or increasingly, 'andropause'. The paper is divided into 2 parts: (1) a review of evidence from physiologic studies conducted over the last decade that examine endocrine function in aging males; (2) a description of the salient features of an ongoing multidisciplinary epidemiologic study (the Massachusetts Male Aging Study) of a sample of approximately 1700 men aged 40-69 yr, randomly sampled from the general population. This study is markedly different in size and content from studies conducted to date. Preliminary findings suggest that age per se may be a relatively unimportant contributor to endocrine variability and that anthropometrics and life style phenomena may be at least as important.

Adult↗
PubMed1991

Estimation of bone turnover in climacteric women by the whole body retention of fluoride.

This paper reports the measurement of whole body retention using fluoride (WBRF) as an estimator of skeletal turnover in a group of climacteric women that received an oral dose of 700 mumol of sodium fluoride. WBRF is defined as 100(1-(urinary fluoride/fluoride load)). WBRF was significantly correlated with whole body retention of 99m-Tc-methylene-diphosphonate, the serum levels of the bone alkaline phosphatase and the urinary excretion of hydroxyproline. WBRF values ranged from 20% to 95% and were affected by calcium intake and the urinary calcium excretion. In normal subjects with high turnover, the measurement of serum alkaline phosphatase activity and/or urinary hydroxyproline excretion helps to distinguish these cases from patients with metabolic bone diseases due to metastases, Paget disease, etc. The fact that the fraction of fluoride not incorporated into bone is not further metabolized plus the accuracy, preciseness and rapidity of fluoride measurements in urine are the main advantages of this technique.

Alkaline Phosphatase↗
PubMed1991

Cardiovascular effects of Org OD 14--a new steroidal therapy for climacteric symptoms.

The cardiovascular effects of Org OD 14, a synthetic steroid which relieves climacteric symptoms without stimulating the endometrium, were assessed in a group of healthy post-menopausal women. Limb blood flow was measured by venous occlusion plethysmography. Resting forearm blood flow, the dilator response to anoxic exercise and heart rate increased significantly after six weeks of drug treatment. Hand flow was unchanged. The cardiovascular effects of Org OD 14 differ from those seen with oestrogens, in keeping with the unique pharmacological profile of this steroid.

Blood Pressure↗
PubMed1992

The cross-sectional legacy: an introduction to longitudinal studies of the climacteric.

Hitherto the bulk of psychosocial and sociological research on the menopause has been based on cross-sectional studies, in which the research strategy has been to compare women of different ages and/or different menopausal status by reference to various parameters. This paper summarizes the main findings of these studies, which relate to a variety of countries. A consistent finding has been that much of the variance in the symptoms and complaints reported by women during the climacteric can in fact be accounted for by a number of different adverse sociodemographic and psychosocial factors. It is postulated that the mechanism whereby these factors exercise their effect can best be conceptualized in terms of a vulnerability model. Although cross-sectional studies, have obvious limitations, their findings have now been complemented by those from a number of ongoing longitudinal studies in which the same cohort of women is being followed through this transitional period of their lives.

Climacteric↗
PubMed1992

The south-east England longitudinal study of the climacteric and postmenopause.

Fifty-six premenopausal women were drawn from a cross-sectional survey of 850 women living in South-East England. They were recontacted 3 years later when 36 met the criterion of being naturally peri- or postmenopausal. Somatic, vasomotor and emotional symptoms, as well as general health, use of medical services and beliefs about the menopause, were assessed on both occasions using the Women's Health Questionnaire (a symptom scale standardized for use with this age group). In general, the cross-sectional findings were confirmed--vasomotor symptoms, sleep problems and to a lesser extent depressed mood increased during the peri- and postmenopause. However, ratings of general health and use of medical services remained unchanged. A stepwise regression analysis was used to predict depressed mood and hot flushes in peri- and postmenopausal women. The results illustrate the importance of previously existing symptoms, stereotyped beliefs and social factors in explanations of climacteric symptoms.

Affect↗